Abstract 42P
Background
Extrapulmonary small cell neuroendocrine carcinoma (EP-SCNC) is an uncommon and aggressive malignancy with a poor prognosis and an incidence rate of less than 0.4%. Most EP-SCNC patients present with metastatic disease, leading to an average overall survival (OS) of less than 12 months. Currently, platinum-based chemotherapy is the standard treatment, but there is no consensus on second-line therapy upon progression. Given the limited effective systemic options for EP-SCNC, identifying new therapeutic targets is crucial. One such target could be the human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase involved in various cancer pathways. This pilot study investigates the mutational status and mRNA expression of the HER2 gene in EP-SCNC.
Methods
A cohort of 192 EP-SCNCs (91 genitourinary, 32 gastrointestinal, 21 gynaecological, 13 unknown primary, 12 pancreatic, 8 head and neck, 8 hepatobiliary, 6 breast, and 1 skin) underwent DNA-targeted panel next-generation sequencing of 788 genes, including HER2. mRNA expression analysis of the HER2 gene was conducted using whole-transcriptome RNA-Sequencing data.
Results
Activating mutations of the HER2 gene were detected in 6/128 (4.7%) EP-SCNCs, including 4 urinary bladder tumours, 1 anal canal tumour, and 1 uterine cervix tumour. Copy number variation (CNV) analysis revealed HER2 gene amplification in 3/83 (3.6%) cases. Gene expression analysis of HER2 across all groups showed median values ranging from 13.79 to 26.37 CPM (TMM-adjusted).
Conclusions
Our study found that 7% (9/128) of EP-SCNCs exhibited either mutation or amplification of the HER2 gene. Additionally, HER2 mRNA overexpression was observed in 6 other samples, suggesting potential overexpression of the HER2 protein. Confirming these findings at the protein level is essential and ongoing. Our preliminary results indicate that HER2 aberration could serve as a potential molecular target for treatment in EP-SCNCs.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Ministry of Health, Czech Republic (MH CZ AZV NU22-03-00130 and DRO-VFN 64165).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - Development of an exo-miRNA panel for metastasis prediction in breast cancer
Presenter: Shafiqa Siddique
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - Molecular characterization of circulating tumor cells in metastatic breast cancer using shallow whole genome sequencing
Presenter: Michela Bulfoni
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy
Presenter: Marcela Carausu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer
Presenter: Sara Gil-Bernabé
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers
Presenter: Weituo Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Comparative analysis of miRNA biomarkers in liquid-based cytology and plasma for early detection of high-grade cervical intraepithelial neoplasia
Presenter: Stéphanie Calfa
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - Integrated proteogenomic approach for discovering potential biomarkers in urothelial carcinoma of the bladder
Presenter: PONGSAKORN CHOOCHUEN
Session: Cocktail & Poster Display session
Resources:
Abstract